These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 32838997)

  • 1. Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Shore ND; Dearnaley D; Tombal B
    Eur Urol; 2020 Nov; 78(5):e196-e197. PubMed ID: 32838997
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Mahal BA; D'Amico AV; Nguyen PL
    Eur Urol; 2020 Nov; 78(5):e195. PubMed ID: 32863056
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer.
    Chow AK; Vourganti S; Konety BR
    Eur Urol; 2021 Sep; 80(3):386. PubMed ID: 34092438
    [No Abstract]   [Full Text] [Related]  

  • 4. Relugolix: Early Promise for a Novel Oral Androgen Deprivation Therapy with Radiation Therapy for Prostate Cancer.
    Sachdev S; Zhang H; Hussain M
    Eur Urol; 2020 Aug; 78(2):193-194. PubMed ID: 32345524
    [No Abstract]   [Full Text] [Related]  

  • 5. First Oral Hormone for Treating Prostate Cancer.
    Aschenbrenner DS
    Am J Nurs; 2021 Apr; 121(4):22-23. PubMed ID: 33755620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relugolix in the management of prostate cancer.
    Sahu KK; Tripathi N; Agarwal N; Swami U
    Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reply to Michael Froehner, Rainer Koch, Manfred P. Wirth's Letter to the Editor re: Jesse D. Sammon, Firas Abdollah, Anthony D'Amico, et al. Predicting Life Expectancy in Men Diagnosed with Prostate Cancer. Eur Urol 2015;68:756-65.
    Sammon JD; Abdollah FA; Trinh QD
    Eur Urol; 2016 Jun; 69(6):e129. PubMed ID: 26461111
    [No Abstract]   [Full Text] [Related]  

  • 8. Prostate Cancer 2020: "The Times They Are a'Changing".
    Paschalis A; de Bono JS
    Cancer Cell; 2020 Jul; 38(1):25-27. PubMed ID: 32663466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re: Matthew R. Smith, Maha Hussain, Fred Saad, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386:1132-1142.
    Di Lorenzo G; Buonerba C
    Eur Urol; 2022 Jul; 82(1):e17. PubMed ID: 35393160
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to John T. Leppert and James D. Brooks' Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. Eur Urol 2018;74:146-54.
    Mahal BA; Yang DD; Nguyen PL
    Eur Urol; 2018 Nov; 74(5):e112-e113. PubMed ID: 30029822
    [No Abstract]   [Full Text] [Related]  

  • 11. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr, University of Michigan, Division of Hematology/Oncology, Ann Arbor, MI. N Engl J Med 2013; 368(14):1314-25. doi: 10.1056/NEJMoa1212299.
    Eggener S
    Urol Oncol; 2014 Aug; 32(6):936-7. PubMed ID: 25087673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Commentary on "Intermittent versus continuous androgen deprivation in prostate cancer." Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr., University of Michigan, Division of Hematology/Oncology, 1500 E Medical Center Dr., 7314 CC, Ann Arbor, MI. N Engl J Med 2013;368(14):1314-25.
    Trump DL
    Urol Oncol; 2013 Nov; 31(8):1847. PubMed ID: 24210086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-114.
    Kishan AU; Spratt DE
    Eur Urol; 2022 Sep; 82(3):e82-e83. PubMed ID: 35688665
    [No Abstract]   [Full Text] [Related]  

  • 15. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
    Kittai AS; Blank J; Graff JN
    Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment.
    Lv J; Lin J
    Asian J Androl; 2021; 23(3):229-230. PubMed ID: 33243960
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Vis AN; Boevé LMS
    Eur Urol; 2019 May; 75(5):e131-e132. PubMed ID: 30616950
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to Leah Bensimon, Samy Suissa, and Laurent Azoulay's letter to the editor re: Daniel E. Spratt, Chi Zhang, Zachary S. Zumsteg, Xin Pei, Zhigang Zhang, Michael J. Zelefsky. metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol 2013;63:709-16.
    Spratt DE; Zhang Z; Zelefsky MJ
    Eur Urol; 2013 Aug; 64(2):e29-30. PubMed ID: 23619389
    [No Abstract]   [Full Text] [Related]  

  • 19. 'Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.' by V. Conteduca, U. De giorgi and G. Lauletta.
    Yang DD; Nguyen PL
    Ann Oncol; 2018 Sep; 29(9):2021-2022. PubMed ID: 30032198
    [No Abstract]   [Full Text] [Related]  

  • 20. Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.
    Conteduca V; De Giorgi U; Lauletta G
    Ann Oncol; 2018 Aug; 29(8):1879-1880. PubMed ID: 29750418
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.